Pafolacianine is approved for identifying malignant ovarian cancer lesions

Share This Post

Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, has been licenced by the Food and Drug Administration for adult patients with ovarian cancer as an adjuvant for interoperative detection of malignant lesions. Pafolacianine is a fluorescent medication that works by targeting the folate receptor, which is overexpressed in ovarian cancer. It’s employed using a Near-Infrared (NIR) fluorescence imaging system that’s been cleared by the FDA for pafolacianine-specific use.

In a single-arm, multicenter, open-label research (NCT03180307), 178 women diagnosed with ovarian cancer or with a strong clinical suspicion of ovarian cancer who were planned to have primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery were evaluated for efficacy. Pafolacianine was given to all of the patients. In addition to standard of care evaluations such as pre-surgical imaging, intraoperative palpation, and normal light examination of lesions, 134 patients got fluorescent imaging evaluation. At least one evaluable ovarian cancer lesion detected with pafolacianine that was not observed by routine visual or tactile inspection was found in 36 (26.9%) of these individuals. In the detection of ovarian cancer lesions confirmed by central pathology, the patient-level false positive rate of pafolacianine using NIR fluorescent light was 20.2 percent (95 percent CI 13.7 percent , 28.0 percent ).

Nausea, vomiting, abdominal pain, flushing, dyspepsia, chest discomfort, pruritus, and hypersensitivity were the most prevalent adverse effects in patients (1%).

Pafolacianine is given intravenously over 60 minutes, 1 to 9 hours before surgery, at a dose of 0.025 mg/kg. Using folate, folic acid, or folate-containing supplements within 48 hours of receiving pafolacianine is not recommended.

View full prescribing information for Cytalux

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form